ROSEN, A TOP-RANKED LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO

Key Takeaways:

• The class period for Novo Nordisk A/S securities runs from May 7, 2025, to July 28, 2025
• The lead plaintiff deadline is September 30, 2025
• Rosen Law Firm specializes in global investor rights litigation
• A class action lawsuit has already been filed
• Investors pay no out-of-pocket legal fees due to a contingency fee arrangement

Introduction

Rosen Law Firm, a global investor rights practice, has issued a call to Novo Nordisk A/S (NYSE: NVO) shareholders who purchased shares between May 7, 2025, and July 28, 2025. The firm highlights an upcoming legal deadline—September 30, 2025—and encourages eligible investors to review their options and potentially join an ongoing class action lawsuit.

Overview of the Lawsuit

According to the law firm’s announcement, investors who acquired Novo Nordisk securities within the defined May-to-July window could be entitled to compensation. A class action lawsuit has already been filed, and Rosen Law Firm believes shareholders may benefit from joining the legal proceedings if they meet the specified criteria.

Deadline and Requirements

The last day to move the court to serve as lead plaintiff is September 30, 2025. A lead plaintiff is a representative who acts on behalf of all class members, helping direct crucial litigation decisions. Missing this deadline may lessen or eliminate the opportunity to participate in any settlement or judgment.

How to Participate

Investors looking to join the class action may do so by contacting Rosen Law Firm. The firm provides a dedicated website link—https://rosenlegal.com/submit-form/?case_id=34168—as well as a telephone number (866-767-3653) and email address (case@rosenlegal.com). Rosen Law Firm operates on a contingency fee basis, meaning there are no up-front costs for those participating in the lawsuit.

About Rosen Law Firm

Rosen Law Firm is described as a top-ranked global investor rights law practice. In its briefing, the firm underscores its experience in pursuing investor claims and its history of roles in high-profile cases. The notice also encourages affected shareholders to seek competent legal counsel for the best outcome in their litigation efforts.

Conclusion

With the legal clock ticking closer to September 30, 2025, Novo Nordisk A/S investors who purchased shares during the designated period may wish to act swiftly. Further details are available from Rosen Law Firm, which stands ready to assist in navigating the class action process for eligible claimants.